Insulin Therapy and Type 2 Diabetes: Management of Weight Gain

被引:32
|
作者
McFarlane, Samy I. [1 ]
机构
[1] SUNY, Div Endocrinol, Coll Med, Downstate & Kings Cty Med Ctr, Brooklyn, NY 11203 USA
来源
JOURNAL OF CLINICAL HYPERTENSION | 2009年 / 11卷 / 10期
关键词
NPH INSULIN; GLYCEMIC CONTROL; DETEMIR; RESISTANCE; GLUCOSE; MELLITUS; RISK; INITIATION; APPETITE; DRUGS;
D O I
10.1111/j.1751-7176.2009.00063.x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The potential for insulin-related weight gain in patients with type 2 diabetes presents a therapeutic dilemma and frequently leads to delays in the initiation of insulin therapy. It also poses considerable challenges when treatment is intensified. Addressing insulin-related weight gain is highly relevant to the prevention of metabolic and cardiovascular consequences in this high-risk population with type 2 diabetes. In addition to lifestyle changes (eg, diet and exercise) and available medical interventions to minimize the risk of weight gain with insulin treatment, familiarity with the weight gain patterns of different insulins may help deal with this problem. The use of basal insulin analogs may offer advantages over conventional human insulin preparations in terms of more physiologic time-action profiles, reduced risk of hypoglycemia, and reduced weight gain.
引用
收藏
页码:601 / 607
页数:7
相关论文
共 50 条